A Harvard-led team is the first to demonstrate the ability to use low-power light to trigger stem cells inside the body to regenerate tissue, an advance they reported in Science Translational Medicine. The research, led by David J. Mooney, Robert P. Pinkas Family Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences (SEAS), lays the foundation for a host of clinical applications in restorative dentistry and regenerative medicine more broadly, such as wound healing, bone regeneration, and more.
The team used a low-power laser to trigger human dental stem cells to form dentin, the hard tissue that
It expects a satisfactory outcome of the 3700 patients who were treated with stem cells until December of 2011, as part of the studies conducted in Cuba on this therapy.
The effects are similar to those from developed countries to avoid most major amputations sick, the newspaper Granma said Porfirio Hernandez, coordinator of the National Group for Regenerative Medicine, Ministry of Public Health.
But he said that the procedure is still in clinical trials with strict selection criteria, although such services are provided in 10 of the 15 provinces of the Caribbean country.
Six of 10 patients treated with the procedure had
BioTime Inc, a biotechnology company that develops and markets products in the field of regenerative medicine, and its subsidiaries OrthoCyte Corporation and LifeMap Sciences reported today a means of manufacturing seven distinct types of cartilage, bone, and tendon cells from human embryonic stem cells. The paper, scheduled to be published online (ahead of print) at 1600 GMT today in the peer-reviewed journal Regenerative Medicine, characterizes the seven cell types generated using BioTime’s proprietary PureStem(TM) technology. The study compared the novel cells with adult stem cells, known as mesenchymal stem cells (MSCs), and revealed properties of the new cell lines
Piece by missing piece, scientists at the Keck School of Medicine of USC are deciphering the powerful gene regulatory circuit that maintains and controls the potential of embryonic stem cells (ESCs) to form any type of cell in the body.
Recent findings by Provost Professor Andrew McMahon, director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, and Qilong Ying, associate professor of cell and neurobiology, underscore the essential role of basic science in paving the way for future medical breakthroughs.
McMahon and Ying are in pursuit of the ways in which the intricate
Stanford stem cell researcher Irving Weissman, MD, published an article in Cell Stem Cell today discussing barriers to stem cell research:
While I am usually an optimist, I must admit that there is a possibility that we will continue to be in the Dark Ages of medicine for quite some time. I fear that therapies using purified tissue and organ-specific stem cells – the only self-renewing cells in a tissue or that can regenerate that tissue or organ for life – will remain elusive.
Weissman, who directs Stanford’s Institute for Stem Cell Biology and Regenerative Medicine, goes on to cover the